应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02616 基石药业-B
已收盘 04-22 16:08:12
2.760
+0.250
+9.96%
最高
2.780
最低
2.540
成交量
480.80万
今开
2.540
昨收
2.510
日振幅
9.56%
总市值
37.65亿
流通市值
37.65亿
总股本
13.64亿
成交额
1,287万
换手率
0.35%
流通股本
13.64亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
基石药业-B04月22日主力净流入28万元 散户资金抛售
市场透视 · 08:17
基石药业-B04月22日主力净流入28万元 散户资金抛售
基石药业-B盘中异动 早盘快速拉升5.58%报2.650港元
市场透视 · 01:47
基石药业-B盘中异动 早盘快速拉升5.58%报2.650港元
基石药业-B盘中异动 早盘急速跳水5.28%报2.510港元
市场透视 · 04-16
基石药业-B盘中异动 早盘急速跳水5.28%报2.510港元
基石药业-B04月15日主力净流出13万元 散户资金买入
市场透视 · 04-15
基石药业-B04月15日主力净流出13万元 散户资金买入
【港股医药股多数走强 再鼎医药涨超13%】截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。
金融界 · 04-14
【港股医药股多数走强 再鼎医药涨超13%】截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。
基石药业-B盘中异动 大幅上涨5.02%报2.510港元
市场透视 · 04-14
基石药业-B盘中异动 大幅上涨5.02%报2.510港元
基石药业-B(02616)：迈向管线2.0，ROR1 ADC潜力十足
智通财经网 · 03-11
基石药业-B(02616)：迈向管线2.0，ROR1 ADC潜力十足
基石药业-B盘中异动 早盘大幅下跌5.28%
市场透视 · 03-10
基石药业-B盘中异动 早盘大幅下跌5.28%
基石药业-B03月06日获主力加仓314万元
市场透视 · 03-06
基石药业-B03月06日获主力加仓314万元
基石药业-B盘中异动 大幅拉升5.04%报3.750港元
市场透视 · 03-06
基石药业-B盘中异动 大幅拉升5.04%报3.750港元
【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。
金融界 · 03-06
【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。
基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请
智通财经 · 03-06
基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请
港股异动 | 基石药业-B(02616)涨超8% 治疗实体瘤药物临床试验顺利完成首例患者给药
智通财经 · 03-05
港股异动 | 基石药业-B(02616)涨超8% 治疗实体瘤药物临床试验顺利完成首例患者给药
基石药业-B盘中异动 股价大涨5.10%报3.300港元
市场透视 · 03-05
基石药业-B盘中异动 股价大涨5.10%报3.300港元
基石药业-B盘中异动 早盘急速下挫5.69%
市场透视 · 03-04
基石药业-B盘中异动 早盘急速下挫5.69%
基石药业(02616)CS2009全球多中心I期临床试验完成首例患者给药
金吾财讯 · 03-04
基石药业(02616)CS2009全球多中心I期临床试验完成首例患者给药
【基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药】基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。
金融界 · 03-04
【基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药】基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。
基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药
智通财经 · 03-04
基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药
基石药业-B盘中异动 早盘快速跳水5.61%报3.530港元
市场透视 · 02-28
基石药业-B盘中异动 早盘快速跳水5.61%报3.530港元
基石药业-B午前涨超8% 宣布舒格利单抗GEMSTONE-303研究数据在JAMA发表
新浪港股 · 02-26
基石药业-B午前涨超8% 宣布舒格利单抗GEMSTONE-303研究数据在JAMA发表
加载更多
公司概况
公司名称：
基石药业-B
所属市场：
SEHK
上市日期：
--
主营业务：
基石药业是一家中国投资控股公司。该公司通过子公司主要从事生物制药产品的研发、生产和销售业务。该公司主要产品是肿瘤免疫治疗疗法和分子靶向药物。该公司主要在中国境内开展业务。
发行价格：
--
{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":2.76,"timestamp":1745309292015,"preClose":2.51,"halted":0,"volume":4808000,"delay":0,"floatShares":1364000000,"shares":1364000000,"eps":-0.07581167374725556,"marketStatus":"已收盘","change":0.25,"latestTime":"04-22 16:08:12","open":2.54,"high":2.78,"low":2.54,"amount":12874445,"amplitude":0.095618,"askPrice":2.77,"askSize":112000,"bidPrice":2.75,"bidSize":48500,"shortable":0,"etf":0,"ttmEps":-0.07581167374725556,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":2.51,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":0.660893,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2529730321","title":"基石药业-B04月22日主力净流入28万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529730321","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529730321?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:17","pubTimestamp":1745309832,"startTime":"0","endTime":"0","summary":"04月22日, 基石药业-B股价涨9.96%，报收2.76元，成交金额1287万元，换手率0.35%，振幅9.56%，量比0.66。基石药业-B今日主力资金净流入28万元，上一交易日主力净流出45万元。该股近5个交易日上涨11.72%，主力资金累计净流入24万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出2152万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171641a6c38d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171641a6c38d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2529622813","title":"基石药业-B盘中异动 早盘快速拉升5.58%报2.650港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529622813","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529622813?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:47","pubTimestamp":1745286427,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘09时47分，基石药业-B股票出现异动，股价快速拉升5.58%。截至发稿，该股报2.650港元/股，成交量85.15万股，换手率0.06%，振幅4.38%。资金方面，该股资金流入75.3085万港元，流出131.651万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为1.98%。其相关个股中，歌礼制药-B、诺诚健华、来凯医药-B涨幅较大，振幅较大的相关个股有博安生物、荃信生物-B、来凯医药-B，振幅分别为15.70%、11.22%、11.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422094707973ffd4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422094707973ffd4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2527891832","title":"基石药业-B盘中异动 早盘急速跳水5.28%报2.510港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527891832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527891832?lang=zh_cn&edition=full","pubTime":"2025-04-16 11:01","pubTimestamp":1744772460,"startTime":"0","endTime":"0","summary":"2025年04月16日早盘11时01分，基石药业-B股票出现异动，股价快速跳水5.28%。截至发稿，该股报2.510港元/股，成交量190.45万股，换手率0.14%，振幅5.66%。资金方面，该股资金流入140.594万港元，流出262.051万港元。基石药业-B股票所在的生物技术行业中，整体跌幅为3.53%。其相关个股中，荃信生物-B、复宏汉霖、贝康医疗-B涨幅较大，振幅较大的相关个股有北海康成-B、歌礼制药-B、创胜集团-B，振幅分别为15.56%、12.00%、8.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416110100a6bc0028&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416110100a6bc0028&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2527246107","title":"基石药业-B04月15日主力净流出13万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527246107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527246107?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:16","pubTimestamp":1744704997,"startTime":"0","endTime":"0","summary":"04月15日, 基石药业-B股价跌0.75%，报收2.65元，成交金额1319万元，换手率0.36%，振幅5.62%，量比0.53。基石药业-B今日主力资金净流出13万元，上一交易日主力净流入23万元。该股近5个交易日上涨19.37%，主力资金累计净流入47万元；近20日主力资金累计净流出1670万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415171604a4597d76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415171604a4597d76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2527945435","title":"【港股医药股多数走强 再鼎医药涨超13%】截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527945435","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527945435?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:42","pubTimestamp":1744594975,"startTime":"0","endTime":"0","summary":"截至发稿，再鼎医药(09688.HK)涨13.51%、来凯医药-B(02105.HK)涨10.34%、基石药业-B(02616.HK)涨6.28%、腾盛博药-B(02137.HK)涨6.17%、药明合联(02268.HK)涨5.94%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/14094249513998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02137","BK4531","02268","BK1588","BK4526","02105","BK4548","BK4139","BK1141","09688","BK1574","BK4585","BK4588","SG9999014674.SGD","LU2488822045.USD","ZLAB","159718","BK1587","BK1161","02616"],"gpt_icon":0},{"id":"2527941648","title":"基石药业-B盘中异动 大幅上涨5.02%报2.510港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527941648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527941648?lang=zh_cn&edition=full","pubTime":"2025-04-14 09:33","pubTimestamp":1744594411,"startTime":"0","endTime":"0","summary":"2025年04月14日早盘09时33分，基石药业-B股票出现异动，股价快速上涨5.02%。截至发稿，该股报2.510港元/股，成交量32.4万股，换手率0.02%，振幅4.18%。资金方面，该股资金流入35.2765万港元，流出6.701万港元。其相关个股中，再鼎医药、科伦博泰生物-B、腾盛博药-B涨幅较大，振幅较大的相关个股有腾盛博药-B、科伦博泰生物-B、再鼎医药，振幅分别为8.02%、7.62%、7.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504140933319736e83d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504140933319736e83d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2518732608","title":"基石药业-B(02616)：迈向管线2.0，ROR1 ADC潜力十足","url":"https://stock-news.laohu8.com/highlight/detail?id=2518732608","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518732608?lang=zh_cn&edition=full","pubTime":"2025-03-11 09:59","pubTimestamp":1741658376,"startTime":"0","endTime":"0","summary":"基石药业是一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，截至2025年2月，公司已成功上市4款创新药、获批16项新药上市申请（NDA以及9项适应症。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250311/20250311100302_75957.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250311/20250311100302_75957.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02616","BK1161","BK4231","BK4080","ADC","BK1574"],"gpt_icon":0},{"id":"2518632922","title":"基石药业-B盘中异动 早盘大幅下跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518632922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518632922?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:52","pubTimestamp":1741575178,"startTime":"0","endTime":"0","summary":"2025年03月10日早盘10时52分，基石药业-B股票出现异动，股价大幅跳水5.28%。截至发稿，该股报3.230港元/股，成交量110.25万股，换手率0.09%，振幅3.81%。基石药业-B股票所在的生物技术行业中，整体跌幅为1.31%。其相关个股中，同源康医药-B、和铂医药-B、奥星生命科技涨幅较大，振幅较大的相关个股有同源康医药-B、来凯医药-B、科笛-B，振幅分别为35.78%、20.08%、19.25%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310105258963f959c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310105258963f959c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2517136073","title":"基石药业-B03月06日获主力加仓314万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517136073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517136073?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:17","pubTimestamp":1741249060,"startTime":"0","endTime":"0","summary":"03月06日，基石药业-B股价收平报3.57元，成交金额3445万元，换手率0.73%，振幅6.16%，量比1.06。基石药业-B今日主力资金净流入314万元，连续3日净流入，上一交易日主力净流入274万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为66.67%，平均涨幅为4.56%。该股近5个交易日下跌4.81%，主力资金累计净流入523万元；近20日主力资金累计净流入3839万元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170451a2622dde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170451a2622dde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2517972404","title":"基石药业-B盘中异动 大幅拉升5.04%报3.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972404","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517972404?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:41","pubTimestamp":1741225285,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时41分，基石药业-B股票出现波动，股价快速上涨5.04%。截至发稿，该股报3.750港元/股，成交量184.35万股，换手率0.14%，振幅4.76%。资金方面，该股资金流入426.485万港元，流出177.93万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，科伦博泰生物-B、创胜集团-B、复宏汉霖涨幅较大，振幅较大的相关个股有华领医药-B、复宏汉霖、百奥赛图-B，振幅分别为7.79%、6.96%、6.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094125a2618866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094125a2618866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2517497936","title":"【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517497936?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","LU1169589451.USD","02616","03347","LU1169590202.USD","BK1161","ADC","BK1574","BK4023","BK4080","PD","BK1576","BK1583","BK4231"],"gpt_icon":0},{"id":"2517763909","title":"基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2517763909","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517763909?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:07","pubTimestamp":1741219667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司已在澳大利亚成功递交CS5001联合标准治疗用于一线弥漫大B细胞淋巴瘤的Ib期临床试验申请。CS5001用于治疗多种实体瘤的全球多中心Ib期临床试验正在同步开展中。本次Ib期临床试验在CS5001单药治疗后线侵袭性和惰性晚期淋巴瘤的数据基础上进一步拓展，旨在深入探索ROR1 ADC在DLBCL全病程的临床应用价值，并持续拓展实体瘤治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK4080","02616","BK1161","BK1574","BK4231","ADC","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2517495018","title":"港股异动 | 基石药业-B(02616)涨超8% 治疗实体瘤药物临床试验顺利完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2517495018","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517495018?lang=zh_cn&edition=full","pubTime":"2025-03-05 14:02","pubTimestamp":1741154541,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超8%，截至发稿，涨8.28%，报3.4港元，成交额1700.51万港元。消息面上，基石药业昨日宣布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。用于治疗多种实体瘤的管线2.0重磅产品CS2009已启动全球多中心临床试验，并率先在澳大利亚递交临床试验申请，未来将陆续扩展至中国及美国。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1583","BK1574","BK1576","BK1161","03347","02616"],"gpt_icon":0},{"id":"2517957487","title":"基石药业-B盘中异动 股价大涨5.10%报3.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517957487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517957487?lang=zh_cn&edition=full","pubTime":"2025-03-05 13:32","pubTimestamp":1741152748,"startTime":"0","endTime":"0","summary":"2025年03月05日下午盘13时32分，基石药业-B股票出现波动，股价急速上涨5.10%。截至发稿，该股报3.300港元/股，成交量439万股，换手率0.34%，振幅5.10%。资金方面，该股资金流入805.363万港元，流出528.334万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为0.78%。其相关个股中，腾盛博药-B、康宁杰瑞制药-B、和誉-B涨幅较大，振幅较大的相关个股有歌礼制药-B、北海康成-B、腾盛博药-B，振幅分别为32.92%、19.60%、16.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305133228963a39f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305133228963a39f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2516948896","title":"基石药业-B盘中异动 早盘急速下挫5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516948896","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516948896?lang=zh_cn&edition=full","pubTime":"2025-03-04 09:37","pubTimestamp":1741052228,"startTime":"0","endTime":"0","summary":"2025年03月04日早盘09时37分，基石药业-B股票出现异动，股价快速下跌5.69%。截至发稿，该股报3.150港元/股，成交量32.25万股，换手率0.03%，振幅4.79%。基石药业-B股票所在的生物技术行业中，整体跌幅为2.63%。其相关个股中，科笛-B、同源康医药-B、荃信生物-B涨幅较大，振幅较大的相关个股有科笛-B、乐普生物-B、来凯医药-B，振幅分别为12.21%、9.63%、9.55%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304093708963855d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304093708963855d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2516269575","title":"基石药业(02616)CS2009全球多中心I期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269575","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516269575?lang=zh_cn&edition=full","pubTime":"2025-03-04 08:47","pubTimestamp":1741049275,"startTime":"0","endTime":"0","summary":"金吾财讯 | 基石药业(02616)公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954249","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK1576","03347","BK1161","02616","BK1574","BK1583"],"gpt_icon":0},{"id":"2516984776","title":"【基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药】基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516984776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516984776?lang=zh_cn&edition=full","pubTime":"2025-03-04 08:10","pubTimestamp":1741047048,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04081048500557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1574","BK1161","PD","02616","BK1141","03347","LU1169589451.USD","BK1576","LU1169590202.USD","BK4023"],"gpt_icon":0},{"id":"2516698610","title":"基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2516698610","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516698610?lang=zh_cn&edition=full","pubTime":"2025-03-04 08:06","pubTimestamp":1741046794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。目前，CS2009率先在澳大利亚开展多中心I期临床试验，未来将陆续扩展至中国及美国。据悉，CS2009是一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，作为靶向大瘤种的三特异性抗体，具备同类首创/同类最优潜力。临床前数据显示，CS2009具有明显优于潜在竞品的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","03347","BK4023","02616","BK1141","PD","BK1574","BK1583","LU1169589451.USD","BK1161","LU1169590202.USD"],"gpt_icon":0},{"id":"2514436906","title":"基石药业-B盘中异动 早盘快速跳水5.61%报3.530港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514436906","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514436906?lang=zh_cn&edition=full","pubTime":"2025-02-28 09:58","pubTimestamp":1740707930,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时58分，基石药业-B股票出现波动，股价大幅跳水5.61%。截至发稿，该股报3.530港元/股，成交量159.5万股，换手率0.12%，振幅6.42%。资金方面，该股资金流入166.721万港元，流出376.902万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为1.40%。其相关个股中，百济神州、正大企业国际、百奥赛图-B涨幅较大，振幅较大的相关个股有科笛-B、宜明昂科-B、腾盛博药-B，振幅分别为14.48%、12.67%、12.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228095851abe00d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228095851abe00d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2514079068","title":"基石药业-B午前涨超8% 宣布舒格利单抗GEMSTONE-303研究数据在JAMA发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2514079068","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514079068?lang=zh_cn&edition=full","pubTime":"2025-02-26 11:58","pubTimestamp":1740542280,"startTime":"0","endTime":"0","summary":" 基石药业-B午前涨超8%，近两周交易日累计涨近60%。截至发稿，股价上涨8.33%，现报3.64港元，成交额2907.816港元。 基石药业-B发布公告，舒格利单抗（择捷美）GEMSTONE-303研究结果在国际顶级医学期刊《美国医学会杂志》主刊正式发表。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-26/doc-inemurfp9036191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02616","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0866},{"period":"1month","weight":-0.3216},{"period":"3month","weight":0.162},{"period":"6month","weight":0.4261},{"period":"1year","weight":1.9186},{"period":"ytd","weight":0.0913}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家中国投资控股公司。该公司通过子公司主要从事生物制药产品的研发、生产和销售业务。该公司主要产品是肿瘤免疫治疗疗法和分子靶向药物。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.062298},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039956},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.10478},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.063703},{"month":5,"riseRate":0.4,"avgChangeRate":0.039766},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097121},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049356},{"month":8,"riseRate":0.333333,"avgChangeRate":0.010588},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033892},{"month":10,"riseRate":0.5,"avgChangeRate":0.015157},{"month":11,"riseRate":0.666667,"avgChangeRate":0.016123},{"month":12,"riseRate":0.5,"avgChangeRate":0.028191}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}